Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
Pfizer Japan said on August 28 that it has grabbed additional indications for its Avastin (bevacizumab) biosimilar for the treatment of “inoperable or relapsed breast cancer” and “ovarian cancer.”Bevacizumab BS Intravenous Infusion 100 mg/400 mg “Pfizer” was rolled out in…
To read the full story
Related Article
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
BUSINESS
- Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…